Introduction

A virus is a small infectious agent ranging from ~ 20 nm to 300 nm in diameter and contains mostly bundles of gene strands of either RNA or DNA as its genome. Viruses are not autonomous organisms and require the host cell environment and cellular factors for their propagation (Bekhit and Bekhit 2014). Due to the intracellular properties of viruses, it is often difficult to design a treatment that inhibits viral replication directly without adverse effects on the infected cells. (Zinser et al. 2018; Bar-On et al. 2018).

Viral infections can be categorized as chronic or acute based on the length of time the infections and symptoms last. Some of the viruses causing the most widespread and harmful chronic infections are hepatitis B virus (HBV), hepatitis C viruses (HCV), herpes simplex virus (HSV), human immunodeficiency virus (HIV), and human papilloma virus (HPV). HIV alone has caused approximately 33 million deaths since the virus was first discovered in 1981 (WHO 2021). Acute viral infections cause several of the most common, severe and rapid infections. This was painfully illustrated in the coronavirus disease 2019 (COVID-19) pandemic (Wu and McGoogan 2020). As of Mar 2021, there are over 123 million confirmed SARS-CoV-2 (severe acute respiratory syndrome coronavirus 2) infected cases worldwide and over 2.7 million COVID-19 deaths (Worldometer 2021). Annually, seasonal influenza epidemics usually cause 250,000–500,000 deaths. However, they could also cause far more severe damage to human lives. For example, the 1918 H1N1 Spanish flu killed an estimated 50 million people, making it one of the worst pandemics in recorded human history (Short et al. 2018). The viral outbreaks like the Ebola virus (EBOV) in West Africa in 2014 received extensive media coverage due to its epidemic potential and high mortality rates of up to 90% (Martinez et al. 2014).

Many compounds have been tested on various viruses for their antivirtal activity in the past few decades, and some novel antiviral compounds are currently in the process of either preclinical or clinical trials (Chaudhuri et al. 2018). Although public health measures and prophylactic vaccines should remain the most effective means for prevetion of virus infection, for many virues vaccines are either not available or are inefficient. In addition, drug resistance is becoming increasingly common due to the expanding numbers of antiviral drugs. Long-term treatment with antiviral nucleoside analogues can cause delayed and, at times, severe mitochondrial toxicity. Kidney injury associated with antiviral drug use involves diverse mechanisms affecting renal transporters and tubule cells (Hussain et al. 2017; Izzedine et al. 2005). Therefore, the ongoing need to fight viral infections requires continued partnerships between medicinal chemists and biomedical researchers to identify and develop novel antiviral agents that are highly efficacious and cost-effective for the management and control of viral infections when vaccines and standard therapies are unavailable or ineffective.

Globally, medicinal plants have been used in traditional health care systems since ancient times and are still the most important source of medicines for the vast majority of the world’s population (Pushpa et al. 2013). Many traditionally used medicinal plants display strong antiviral activities, and some of them are used to treat animals and people who suffer from viral infections. In 2006, polyphenon E®, a partially-purified extract of green tea (Camellia sinensis) was approved as the first ever botanical drug by the US FDA to treat genital warts caused by HPV. Furthermore, recent studies showing the antiviral potential of plant extracts against viral strains resistant to conventional antiviral agents have contested modern drug discovery practices (Akram et al. 2018). Therefore, exploring the natural antiviral constituents of medicinal plants has garnered widespread and increased interest.

During the last 30 years, numerous broad-based screening programs have been carried out throughout the world to evaluate the inhibitory effects of medicinal plants on several viruses using in vitro and in vivo assays. For example, the Boots drug company (Nottingham, England) screened 288 plants for anti-influenza activity, and 12 of these plants were discovered to be effective against influenza viruses (Mukhtar et al. 2008). In another study, a joint international drug discovery program evaluated the antiviral effects of 3,760 plants extracts in Vietnam and Laos, which led to the identification of more than 90 plant leads that showed anti-HIV and anti-bird flu virus activities (Zhang et al. 2016; Rumschlag-Booms et al. 2011).

Lignans, constituted by the union of two phenylpropane units, are a large class of plant secondary metabolites with diversified chemical structures with many being biologically active including the US FDA approved anticancer drugs etoposide and teniposide (Newman and Cragg 2020). They have been found rich in fruits, seeds and vegetables, and received widespread interest due to their various biological activities including antioxidant, antitumor, antibacterial, antiviral, insecticidal, fungistatic, estrogenic, and antiestrogenic activities (Teponno et al. 2016). Their activity against the coronavirus SARS 2003 was also reported to be prominent (Wen et al. 2007).

The first antiviral lignan reported is podophyllin, a toxic lignan obtained from Podophyllum peltatum with antiviral activity against papilloma virus in 1942 (Kaplan 1942). Charlton had reviewed 49 natural lignans with antiviral activity from 1942 to 1997 (Charlton 1998). In a recent review article, Cui et al. reported about 25 representative lignans that showed antiviral activities (Cui et al. 2020). However, more than 600 lignans have been reported for their antiviral effects since 1998, and many of them showed potent properties. It’s therefore necessary to present a systematic review to include these antiviral lignans.

The present review summarizes the natural antiviral lignans or derivatives from 1998 to 2020. The lignans will be classified in 9 categories according to their chemical structure classes. Their antiviral activities against HIV, HBV, HCV, SARS, herpes simplex virus (HSV), HPV, Ebola virus, influenza virus, vesicular stomatitis virus (VSV) and other viruses will be discussed in detail. The antiviral mechanism studies of lignans will also be included when they were reported.

Arylnaphthalene-type lignans

figure a

In arylnaphthalene lignans, a naphthalene ring-system is made with carbons 1–8 and 7′ and 8′. There have been numerous arylnaphthalene lignans discovered from natural sources. Among the most common structural motifs found in this class of lignans, as with all classes of lignans, are various substitutions on the aromatic rings, a lactone moiety formed from C-8, C-9, C-8′, and C-9′, and glycosides. Many lignans in this class showed significant and broad antiviral activities, warranting them for further chemical and biological approaches for antiviral drug development.

Between 1998 and 2020, 17 arylnaphthalene lignans were isolated from plants and tested for antiviral activity (1–13, 32, 152 and 153) (see Table 1 for source plants, antiviral activities, and references). Of particular interest due to their potent antiviral activity (< 1 μM), are 2 and 11. We found four studies on synthetic arylnaphthalene lignans which displayed significant antiviral activities and provided information about structure–activity relationships.

Table 1 Natural lignans from plants and their antiviral activities
Full size table

Globoidnan A (2) was considered responsible for the inhibitory activity of HIV integrase of the extract of the buds of Eucalyptus globoidea Blakely (Australia). The lignan was found to inhibit the combined 3′-processing and strand transfer activity of HIV integrase with an EC50 value of 0.64 μM (Ovenden et al. 2004). Diphyllin (11) from Justicia procumbens var. leucantha was determined to have antiviral activity with an MIC value of 0.66 µM against vesicular stomatitis virus (Asano et al. 1996). It was also identified as a novel v-ATPase blocker against influenza viruses (Chen et al. 2013). It could alter cellular susceptibility to influenza viruses through the inhibition of endosomal acidification, thus interfering with downstream viral replication, including that of known drug-resistant strains. Moreover, the combination treatment of the host-targeting diphyllin with pathogen-targeting therapeutics (oseltamivir and amantadine) has been reported to enhance the antiviral effects and cell protection in vitro (Chen et al. 2013; Shen et al. 2011).

figure b
figure c

Phyllamycin B (12) and retrojusticidin B (13), obtained from Phyllanthus myrtifolius Moon (Euphorbiaceae, Taiwan, China), exhibited inhibitory effects on HIV-1 RT with EC50 values 3.5 and 5.5 µM. They showed less inhibition activities on human DNA polymerase-α (HDNAP-α) with EC50 values more than 200 µM (Chang et al. 1995). Interest in the antiviral activities of 12 and 13 led to the synthesis and bioassay of 18 derivatives (14–31) including a range of nitrogen containing azalignans including 1-aryl-pyrronaphthalenes 23–27 and 3-N-alkylaminomethyl-1-arylnaphthalenes 28–31. The results indicated that compounds 17, 25, 26, and 31 have good activity against HIV, with EC50 values of 0.77, 2.63, 0.02, 0.71 µM, respectively. It was noted that in the 9, 9′-γ-lactone series (16–18), the dicatechol 17 that contains four hydroxyl groups are much more active than the tetramethoxy (16) and dimethylenedioxy (18) derivatives. In addition, the N-isobutyl azalignans 26 and 31 were the most active among the series of compounds 23–31. Interestingly, N-isobutyl-pyrro[4,3-b]naphthalene (26) possessed the highest activity (EC50 = 0.024 µM) with an excellent therapeutic index (TI) (6,000). Therefore, this compound could act as a lead compound for further anti-HIV drug development (Sagar et al. 2004).

figure d

Helioxanthin (32) was used as a scaffold to create 45 analogues (33–77) with particular attention paid to the lactone ring and methylenedioxy group, these synthetic analogs were evaluated for their antiviral activities against HBV, HCV, HSV-1, HSV-2, Epstein-Barr virus (EBV), cytomegalovirus (CMV) and HIV (Yeo et al. 2005). Of these analogues, the lactam 49 and the cyclic hydrazide derivative of helioxanthin (59) exhibited significant in vitro anti-HBV activity with EC50 values of 0.08 and 0.03 µM, respectively, and compound 49 was also found to be the most potent HCV inhibitor (55% inhibition at the concentration of 1.0 µM). Compound 43, the acid-hydrolyzed product of the cyclic amide 40, displayed more potent activity than 32 against HBV with an EC50 value of 0.8 µM. In addition, compounds 46 and 53, containing dimethoxy moieties instead of methylenedioxy groups in the C ring of compounds 43 and 49, displayed potent antiviral activities against HCV (64% and 80% inhibition at 3.0 µM, respectively) as well as HBV (EC50 = 0.8 and 0.9 µM, respectively). Compounds 43 and 49 were found to be the strongest HSV inhibitors. They showed inhibitory activity against HSV-1 with EC50 values of 0.15 and 0.29 µM, respectively, and against HSV-2 with EC50 values of < 0.1 and 0.16 µM, respectively. Compound 43 was further determined to have broad-spectrum antiviral activity against HSV-1 (EC50 = 0.15 µM), HSV-2 (EC50 < 0.1 µM), EBV (EC50 = 9.0 µM) and CMV (EC50 = 0.45 µM). This compound was approximately 140 and 210 times more potent than the reference drug acylovir (EC50 = 21 µM) against HSV-1 and HSV-2, respectively. The cyclic hydrazide 59 and its brominated product 73 showed anti-HIV activities with EC50 values of 2.7 and 2.5 µM, respectively (Yeo et al. 2005). Moreover, as established by quantification of viral DNA, RNA, covalently closed circular DNA, and protein synthesis, compound 59 inhibited duck HBV (DHBV) activity without affecting the stability of cellular macromolecules, and it had a sustained antiviral effect even after drug removal. When DHBV replication was induced, virus-harbouring cells were more susceptible to the cytotoxicity of the compound than the non-induced cells (Ying et al. 2010).

In a study of inhibitors of HBV gene expression and replication, compound 32 and its lactam analogue 49 demonstrated strong anti-HBV activity by markedly decreasing HBV DNA, 3.5-kb and 2.4/2.1-kb RNA, and the core protein in HepG2.2.15 cells. Compounds 32 and 49 revealed EC50 values of 1.0 and 0.08 µM against HBV DNA, and 1.0 and 0.09 µM against HBV RNA (3.5 kb), respectively. In addition, western blot analysis of the cell lysate from HepG2.2.15 cells confirmed that the core protein expression decreased in a dose-dependent manner after drug treatment. Moreover, the EC50 values for compounds 32 and 49 as inhibitors of HBV DNA production were determined to be 0.4 µM and 0.004 µM against the drug-resistant mutant W10, and 0.1 µM and 0.0003 µM against the drug-resistant mutant DM2, respectively (Li et al. 2005b; Cheng et al. 2005a; Tseng et al. 2008).

In a study of the anti-HBV mechanism, compound 59 was found to suppress HBV RNA and protein expression as well as DNA replication of both the wild-type and 3TC-resistant virus. In addition, the time-course analyses revealed that RNA expression was inhibited first after treatment with compound 59, followed by viral proteins, and then DNA. This compound inhibited the activity of all HBV promoters by decreasing the binding of hepatocyte nuclear factor (HNF)-4, HNF-3, and fetoprotein factor to the precore/core promoter enhancer II region. Therefore, compound 59 suppressed HBV replication by posttranscriptional downregulation of critical transcription factors in HBV-producing cells, thus reducing HBV promoter activity and blocking viral gene expression and replication (Ying et al. 2007; Quasdorff & Protzer 2010).

figure e
figure f
figure g

Yeh et al. also synthesized series of helioxanthin analogues (78–110) by modification at the lactone rings. These compounds were evaluated for their anti-HBV activity in HepA2. Among them, helioxanthin (32) and the derivative 103 were found to possess the best activity (EC50 = 0.16 µM and 0.14 µM, respectively), whereas the retro-isomer 79 (EC50 = 2.18 µM) is less active. Interestingly, compound 105 differs from 103 only by switching the locations of the hydroxyl (OH) and the methoxy (OCH3) groups, yet its anti-HBV activity was markedly reduced to an EC50 value of 1.89 µM. The γ-lactam ring opening analogues 84, 89, 90 and 91 exhibited antiviral activity against HBV with EC50 values of 0.89, 1.41, 0.42 and 1.22 µM, respectively. Analogues 93, 108 and 109 exhibited moderate to low anti-HBV effects (EC50 = 2.39, 3.06 and 7.64 µM, respectively), while all other compounds did not display detectable anti-HBV effects within the same range of concentrations. Compound 103 potently suppressed both endogenously expressed HBsAg and HBeAg production with EC50 values of 0.06 and 0.14 μM, respectively. It not only inhibited HBV DNA with wild-type (stably transfected with 1.3-fold wild-type HBV ayw strain genome in HepG2 cells) and lamivudine-resistant (HepG2 cell line [HBV] containing the lamivudine-resistant HBV with L515M/M539V double mutation in the DNA polymerase region) strains, but also suppressed all HBV transcripts and HBV core protein in 1.3 ES2 cells. Additionally, it could selectively suppress viral promoter activity for HBV surface antigen, core antigen and enhancer I in HepA2 cells (Janmanchi et al. 2010).

figure h

Helioxanthin analogues 103, 105, 108, 111–150) were also synthesized and evaluated for their anti-hepatitis B virus activity. Among them, 112 exhibited the strongest inhibition (EC50 value 0.06 μM), which was about three times more active than its parent compound (32). Potent activities were also found for the fluorine containing 117, the γ-lactone ring opening 129–131 and the lactone group containing 147 with EC50 values of 0.38, 0.67, 0.49, 0.65 and 0.86 μM, respectively. From these synthesized arylnaphthalene lignans, no distinguished structure–activity relationship could be concluded. However, it is obvious that the retro-lactonization and the ring opening of the lactone group do not lower the anti-HBV activity. The most effective compound, 112, not only suppressed HBsAg production in HepA2 cells and viral replication of HBV (stably transfected with 1.3-fold wild-type HBV ayw strain genome in HepG2 cells), but also inhibited all HBV transcripts in 1.3ES2 cells and viral core promoter activity in HepA2 cells (Janmanchi et al. 2013).

Justiprocumins A (151) and B (152), patentiflorin A (153) were obtained from Justicia gendarussa Burm. f. and Justicia cf. patentiflora Hemsley (Vietnam). Compounds 152 and 153 displayed potent activity against a broad spectrum of HIV strains with EC50 values in the ranges of 15–37 nM (AZT, EC50 77–95 nM). They also showed potent inhibitory effects against drug-resistant HIV-1 isolates (HIV-11617–1/HIV-1N119) of both the nucleotide analogue (AZT) and non-nucleotide analogue (nevaripine) with EC50 values in the ranges of 47–495 nM (Zhang et al. 2017a, 2017b). In this study, the C-7 sugar unit-containing compounds (151, 153) display better anti-HIV activity than their aglycone diphylin (11). Compound 153 also exhibited potent inhibitory activity against Zika virus (ZIKV) infection in vitro and in vivo, a mosquito-borne flavivirus that causes microcephaly and severe brain malformations in fetus. It blocked ZIKV infection in African greenmonkey kidney epithelial cells (VERO), human fibroblast cells (HT1080), and human microglial cells (CHME3) with EC50 values between 0.01–0.03 μM. The result was confirmed in vivo by using type I interferon receptor knockout mouse model C57BL/6 Ifnar1−/−. Compound 153 also showed a broad spectrum inhibition against other Flaviviridae viruses including DENV1, tick-borne encephalitis virus (TBEV), West Nile virus (WNV), JEV and EBV with the EC50 values ranged between 0.12–1.0 μM (Martinez-Lopez et al. 2019).

Aryltetralin-type lignans

figure i

Aryltetralin lignans have a 10-membered bicyclic core, with two aromatic ring systems. Unlike arylnaphthalene lignans, which involve all three rings being aromatized, aryltetralin lignans have a variety of configurations possible in the non-aromatic ring (ring B) formed by fusion of the two phenylpropanoid units. This leads to a greater diversity of possible isomers and stereochemical outcomes in aryltetralin lignans. We have included lignans bearing a dialin ring-system in this section, since they also contain stereocenters in the core of the molecule and are not typically recognized as a separate class of lignans. The most well-known lignan of this type of compounds may be podophyllotoxin. The compound was discovered from Podophyllum peltatum L. in 1880 (Cragg et al. 2011). Two of its derivatives, etopside and teniposide, were granted as anticancer medications by the US FDA in 1983 and 1992, respectively (Hande 1998; Cragg and Newman 2005).

During the time covered by this review, 31 aryltetralin lignans isolated from plants were tested for antiviral activity (154–181, 224–226) (see Table 1 for source plants, antiviral activities, and references). Of the plant-derived aryltetralin lignans, only compounds 157, 162, and 165 displayed antiviral activity at concentrations below 5 μM. There were three studies on synthetic podophyllotoxin analogues which displayed significant antiviral activities and provided information about structure–activity relationships.

figure j

In an ongoing study of the chemical composition of Streblus asper Lour. (Moraceae, Guangxi, China), Li et al. isolated (-)-isolariciresinol (157) and 9-β-xylopyranosyl-(-)-isolariciresinol (158) from the plant’s roots. In tests for potential inhibition of the secretion of HBV s antigen (HBsAg) and HBV e antigen (HBeAg), and the replication of HBV DNA in HBV-infected HepG2.2.15 cells, compounds 157 and 158 displayed anti-HBV activity of EC50 values of 3.67 and 6.98 μM for HBsAg with TI values 35.28 and 30.15, and EC50 values of 14.67 and 26.74 μM for HBeAg with TI values 8.82 and 7.87, respectively. In addition, the compounds showed inhibitory activity on the replication of HBV DNA with EC50 values of 12.72 and 17.68 μM and TI of 10.18 and 11.90, respectively (Li et al. 2013). Compounds 158, 5-methoxy-9-β-xylopyranosyl-(-)-isolariciresinol (159) and 9-β-xylopyranosyl-lyoniresinol (160) were obtained from the stem bark. The only difference of 160 from 158 is that it contains an extra methoxyl group in ring C, and its difference from 159 is that it is lacking an methoxyl group in ring A. Compounds 158 and 159 inhibited the expression of HBsAg and HBeAg with EC50 values of 6.58 and 39.56 μM for HBsAg (TI > 2), and 24.86 μM (TI = 8.06) and 61.23 μM (TI = 1.75) for HBeAg, respectively, while 160 showed no activity against HBV at the concentration of 1000 μM (Li et al. 2012a).

Three new aryltetralin lignans, sinensisins A-C (162–164) and the known (8R,7′R,8R)-5-hydroxy-4,3′,4′-trimethoxy-2,7′-cyclolignan (165) were isolated from the aerial parts of Schisandra propinqua (Wall.) Hook. F. et Thoms. var. sinensis Oliv. (Sichuan, China) and tested for HIV-1 inhibitory effects in a microtiter syncytium formation infectivity assay. Among them, both 162 and 165 displayed anti-HIV-1 activity with EC50 values of 4.5 μM and TI values of 6.7 (Li et al. 2012b, 2009a; Lei et al. 2007).

figure k

Thirteen podophyllotoxin derivatives (182–194) containing modifications in the phenyl C-ring or the lactone ring were prepared and evaluated for their antiherpetic activity against HSV-2 on Vero cells. Among them, phenazines 192 and 193 showed the highest antiviral potency against HSV-2 (Castro et al. 2003).

figure l

A series of derivatives (195–216) of podophyllotoxin with structural modifications mostly at C-7 were synthesized and tested for their inhibitory effects of HIV-1 replication in acutely infected H9 cells. Among the derivatives, the 4-amino derivatives 213–216 were the strongest HIV inhibitors exhibiting EC50 values of < 0.002 μM and TI values > 120. The 4-amino substituted compounds 199 and 203 also displayed strong HIV activity with EC50 values of 0.021 and < 0.002 μM and TI values of 19.1 and > 16, respectively. The 4β-hydroxyl containing compound 197 and its corresponding vinyl carbamate 208 were the strongest HIV inhibitors among the non-nitrogen containing derivatives with EC50 values of 0.14 and 0.072 μM, respectively. However, compound 210, which contains a 4α-hydroxyl group showed less inhibitory activity with an EC50 value of 0.90 μM and a TI value of 19.4. Comparison of the anti-HIV activity of these derivatives suggested that the methylenedioxy group of C-4 and C-5 being substituted by two methoxy groups enhanced the anti-HIV activity (Zhu et al. 2004).

figure m
figure n

In 2007, a new series of podophyllotoxin derivatives (217–223) some of which contained the antiviral drug molecule stavudine and different structural podophyllotoxin analogues were designed, synthesized, and tested for their inhibitory activity against HIV-1 replication in acutely infected C8166 cells by Tu et al. Among these compounds, 219 and 220 showed the highest anti-HIV-1 activities with EC50 values of 0.29 and 0.17 μM and TI values of 354.5 and 466.9, respectively. Moreover, the 7β–cyano-substituted 4,5–dimethoxy compound 222 also showed promising anti-HIV activity (EC50 = 1.05 μM and TI = 131.28). However, compound 223, which is a carboxylic acid derivative of podophyllotoxin obtained by hydrolyzation of 222, was significantly less active than 222 with an EC50 value of 46.90 μM and a TI value > 9.31 (Chen et al. 2007).

Dibenzylbutyrolactone-type lignans

figure o

Dibenzylbutyrolactone lignans are defined by the presence of a five-membered lactone ring formed by the cyclization of oxidized C-9 and C-9′ carbons. Similar to the aryltetralin lignans, this type of lignan may possess a wide variety of relative and absolute configurations, leading to a large number of isomers. The lactone ring in dibenzylbutyrolactone lignans is reminiscent of the lactones frequently observed in the structures of the previously discussed arylnaphthalene and aryltetralin lignans. Most of this type of lignan showed insignificant antiviral activity, although a few of them were studied in mice for their antiinfluenza activity.

From 1998 to 2019, 22 dibenzylbutyrolactone lignans were isolated from plants and tested for antiviral activity (227–248) (see Table 1 for source plants, antiviral activities, and references). Compounds 236, 243, 245, and 248 are worthy of additional discussion due to their potent antiviral activity (≤ 1 μM). Interestingly, considering the potent activity of the four aforementioned potently active compounds, we could find no studies on antiviral activities of synthetic dibenzylbutyrolactone lignans.

figure p

Phenaxolactones 1–5 (234–238) were isolated from the leaves of Phenax spp. (Urticaceae, USA). Compound 234 showed anti-HIV activity with an EC50 value of 3.0 µM and TI value of 37.3. Compound 236 exhibited increased anti-HIV activity with an EC50 value of 0.8 µM but lower TI value of 12.5, while 237, the glycosylated derivative of 236, showed less activity with an EC50 of 2.8 µM and TI of 6.4. Moderate antiviral activity was observed for 235 (EC50 of 5.0 µM and TI of 15.0) and 238 (EC50 of 5.2 µM and TI of 14.4) (Piccinelli et al. 2005; Rastrelli et al. 2001).

Hinokinin (243), isolated from a Phyllanthus species, significantly inhibited both HBsAg and HBeAg production with inhibitions of 33.9% and 68.3% at a concentration of 50 µM, respectively. ( +)–trans–8-(3,4-(Methylenedioxybenzyl)-8′-(3′,4′-dimethoxybenzyl)-butyrolactone (244), and a tannin virgatyne were found to have no antiviral activity (Huang et al. 2003a). Purified from the heartwood of Chamaecyparis obtusa (Cupressaceae, Taiwan, China), 243 and savinin [245, the enantiomer of isogadian (240)] showed high inhibitory activity in the cell-based assay utilizing CPE on Vero E6 cells via SARS-CoV infection at the concentration of 20 μM. In the evaluation for inhibition of SARS-CoV replication using ELISA, 243 had an EC50 value higher than 10 μM, but the EC50 value of 245 was determined to be much more potent with a value of 1.13 μM (TI > 667). In the test for inhibitory effect of SARS-CoV 3CL protease activity, 243 and 245 displayed EC50 values of > 100 and 25 µM, respectively, and a Ki value for 245 was determined to be 9.1 μM in the study of the inhibitory mechanism (Wen et al. 2007). Isolated from the root bark of Zanthoxylum ailanthoides (Rutaceae, Taiwan, China) as well, hinokinin (243) displayed significant anti-HIV-1 activity with an EC50 value of < 0.28 μM and a TI value of > 18.7 in the test for inhibition of HIV replication (Cheng et al. 2005b).

Trachelogenin (248), obtained from the stems and leaves of Trachelospermum jasminoides (Lindl.) Lem., exhibited anti-HCV potential with EC50 values of 0.87 μM (in HCVcc model) and 0.69 μM (in HCVpp model). Compound 248 was a HCV entry inhibitor by interfering with the interactions between HCV glycoprotein E2 and the host entry factor CD81 (Qian et al. 2016).

Dibenzylbutane-type lignans

figure q

Dibenzylbutane lignans bear the least modified connections between the 8 and 8′ carbons of the phenylpropanoid precursors. This class also contains a large number of stereoisomers due to the chiral carbons created by linking C-8 to C-8′. The carbons derived from C-9 and C-9′ are found in a variety of oxidation states varying from methyl groups to carboxylic acid functionalities. As with benzylbutyrolactones, this type of lignans is also lacking lead molecules that show attractive antiviral activities.

We found records of 29 dibenzylbutyrolactone lignans isolated from plants and tested for antiviral activity (249–262, 269, 280–287) (see Table 1 for source plants, antiviral activities, and references). Compounds 259 and 285 displayed the most activity in antiviral assays (< 5 μM). There were 10 synthetic dibenzylbutryolactones published between 1998 and 2020, most of which were modeled off of nordihydroguaiaretic acid (NDGA) (269).

figure r

Nordihydroguaiaretic acid (NDGA) (269), a lignan obtained from the leaves and twigs of Larrea tridentate, was evaluated for its anti-dengue virus (DENV) effects. It displayed a dose-dependent inhibitory effects on the viral yield and nonstructural protein-1 secretion in the supernatants of infected cells treated for 24 and 48 h. In DENV4 replicon-transfected Vero cells, treatment with 269 at 50 and 100 μM significantly reduced DENV replication. Furthermore, treatment with this compound not only led to the reduction in the number of lipid droplets (LDs), the neutral lipid storage organelles involved in DENV morphogenesis that are known to proliferate during DENV infection, but also resulted in dissociation of the C protein from LDs (Soto-Acosta et al. 2014). Compound 269 was assessed for its ability to elicit HIV replication. It was demonstrated to increase the HIV-1 p24 antigen two fold at the concentration of 15 μM. In addition, the treatment of 269 at 15 μM also increased reactive oxygen species production in U1 cells up to 140% compared with control cells (Barquero et al. 2014). Compound 269 was tested as an HPV16 E6 gene inhibitor. This compound was shown to inhibit HPV16 E6 mRNA expression, influence E6 gene transcription, and induce decreased protein expression levels of E6 and p53 (Chen et al. 2008). In an investigation on host lipid/fatty acid synthesis and the HCV life cycle, 269 canceled the HCV-induced alteration of host lipid homeostasis. This compound not only reduced sterol regulatory element-binding protein activation and increased the expression of the genes involved in β-oxidation, but it also inhibited very-low-density lipoprotein (VLDL) secretion by affecting mediators of VLDL biosynthesis. Whereas HCV induced the accumulation and perinuclear distribution of LDs, 269 decreased the overall number and increased the average size of the LDs (Syed and Siddiqui 2011). Furthermore, when 269 was added simultaneously with the virus, it could inhibit Junin viral replication (Konigheim et al. 2005).

figure s

Tetra-O-glycyl-NDGA (270), a water-soluble derivative of 269, competed effectively with the DNA binding domain of recombinant Sp1 protein to bind to the HIV long terminal repeat, as determined by an electrophoretic mobility-shift assay. By inhibiting Sp1 binding to the HIV long terminal repeat, 270 repressed Sp1-regulated HIV Tat transactivation and replication in cultured cells, with an EC50 of 12 μM. Moreover, replication of simian immunodeficiency virus was completely blocked by 270 at a concentration of 5.0 μM. Furthermore, at 100 μM, 270 was harmless towards 174 × CEM cells and H9 cells (Huang et al. 2003b).

Nine synthesised NDGA derivatives 271–277, Mal.4 (278), and M4N (279) inhibited Tat transactivation in a dose-dependent manner. At 80 μM, these compounds blocked Tat-regulated secreted alkaline phosphatase production by > 90%; and at 20 μM, the inhibition was still > 50%. All of these newly synthesized derivatives showed a greater inhibitory activity than the parent NDGA 269 (EC50 = 20 μM) and Mal.4 (278, EC50 = 25 μM). Except for compounds 271 (EC50 = 17.2 μM) and 273 (EC50 = 17.3 μM), all other NDGA derivatives demonstrated greater potency than M4N (279, EC50 = 11.1 μM). Compound 272 (EC50 = 0.88 μM) was determined to be the strongest inhibitor of HIV Tat-regulated transactivation among all of the new NDGA derivatives (Hwu et al. 2008). Furthermore, three synthesized NDGA derivatives, tetra-acetyl NDGA (280), 278 and 279, were all demonstrated to inhibit gene expression from the early promoter P97 of HPV16. Using luciferase activity as the indicator of gene expression, compounds 278 and 279 were shown to be active in a dose-dependent manner. However, 280 (EC50 = 11 μM) was shown to be a better inhibitor of the HPV P97 promoter activity than 278 (EC50 = 37 μM) and 279 (EC50 = 28 μM). These compounds demonstrated very little effect on the gene expression guided by the ADV major late promoter and the CMV promoter (Craigo et al. 2000; Halim et al. 2013). Compound 279 inhibited 10 passages of HSV-1 and 4 passages of HSV-2 with the EC50 values ranges 4–11.7 μM, while the EC50 ranges of ACV increased from 7 μM to 444 μM. The results indicated that 279 had less drug resistance than ACV. Compound 279 inhibited HSV by decreasing the expression of the HSV immediate early gene α-ICP4 with an EC50 value of 43.5 μM, which was essential for HSV replication (Chen et al. 1998).

Compound 281, 3,3′-Dihydroxy-4,4′,5,5′-tetramethoxylignan, was isolated from the fruits of Schisandra rubriflora (Yunan, China). It showed inhibitory activity on HIV-1IIIB induced syncytium formation with an EC50 value of 5.8 µM and a TI value of 4.46 (Xiao et al. 2010a). Kadangustins H (282) and I (283), meso-dihydroguaiaretic acid (259), tiegusanin N (284), meso-monomethyldihydroguaiareticacid (285) and 279 were isolated from the stems of Kadsura angustifolia (Yunnan, China). The compounds showed anti-HIV activity with EC50 values of 27.0, 21.5, 15.6/4.0, 2.9 and 14.8 μM, and TI values of 2.8, 1.1, 3.2/6.2, 5.8 and 2.0, respectively (Gao et al. 2008; Li et al. 2009b).

Tetrahydrofuranoid and tetrahydrofurofuranoid-lignans

figure t

Tetrahydrofuranoid lignans have a characteristic five-membered oxygen-containing ring connecting the two phenylpropanoid precursor units. This ring can be derived from a C-7 and C-8 to C-7′ and C-8′ linkage (7,8,8′,7′-tetrahydrofuranoid lignans, compounds 294–311, 313–323, 334–336, 338, 340, 379–388), a C-7 and C-8 to C-8′ and C-9′ linkage (7,8,8′,9′-tetrahydrofuranoid lignans, compounds 291, 292, 324, 325, 327, 337, 339, 344, 346, 347, 376–378, 390 and 391), or a C-8 and C-9 to C-8′ and C-9′ linkage (9,8,8′,9′-tetrahydrofuranoid lignans, compounds 288–290, 333 and 389). This diversity of precursor orientations, combined with the possibility of stereoisomers leads to a large diversity of possible isomers being isolated. Tetrahydrofurofuranoid lignans are defined by the presence of a bicyclic furofuran ring-system formed by the connection of C-7 to C-9′ through an oxygen atom, and a connection between C-9 and C-7′ through an oxygen atom (tetrahydrofurofuranoid lignans, compounds 293, 312, 326, 328–332, 341–343, 345, 348–375).

The antiviral activity of 104 plant-derived tetrahydrofuranoid and tetrahydrofurofuranoid lignans were reported between 1998 and 2020 (288–391) (see Table 1 for source plants, antiviral activities, and references). Five compounds in this class (290, 379–381, 388) displayed antiviral activity at concentrations of 1 μM or less. We did not find any antiviral studies on synthetic tetrahydrofuranoid or tetrahydrofurofuranoid lignans during the time period covered in this review.

4,4′-Dihydroxy-3,3′-dimethoxy-9-ethoxy-9,9′-epoxylignan (289) and daphnenin (290), are two lignans that were isolated from the stems of Daphne acutiloba (Thymelaeceae, Yunan, China). Compound 290 showed anti-HIV activity with an EC50 value of 0.64 µM (Huang et al. 2012).

figure u
figure v
figure w
figure x
figure y
figure z
figure aa

Manassantins A–B (379–380) and saucerneols B–C (381–382) were isolated from Saururus chinensis (Saururaceae, Korea) rhizomes and evaluated for their anti-HIV-1 activities. Compound 379 showed dose-dependent inhibitory activities on HIV-1 protease with an EC50 value of 38.9 μM. Compounds 379–381 inhibited HIV-1-induced cytopathic effects in a human T lymphoblastoid cell line with EC100 values of 1.0, 1.0 and 0.2 μM, respectively. Compound 381 showed the most potent and selective anti-HIV-1 activity with an EC100 value of 0.2 μM, a CC0 value of > 125.0 μM, and a TI value of > 520.8 (Lee et al. 2010b). Nine tetrahydrofuran lignans, (–)–(7"R,8"R)–saucerneol J (321), manassantins A–B (379–380), saurucinol B (383), 4′′-O-demethylmanassantin A (384), 3′′-O-demethylmanassantin B (385), 4–O–demethylmanassantin B (386), saucerneol methyl ether (387) and saucerneol D (388) were isolated from the roots of S. chinensis (Saururaceae, Guangxi, China). In the examination for their abilities to inhibit EBV lytic DNA replication in P3HR-1 cells, these compounds showed strong to moderate activities with EC50 values of 6.95, 3.42, 1.72, 14.5, 7.55, 2.69, 3.52, 1.70 and 1.09 μM, and TI values of 3.3, 58.5, 116.4, 4.4, 9.2, 20.2, 20.2, 65.0 and 41.1, respectively (Cui et al. 2014).

Benzofuran lignans

figure ab

Benzofuran lignans are determined by the presence of a furan juncture created from the linkage of C-7 to C-4′ through an oxygen atom and the direct linkage of C-8–C-3′. Due to the phenylpropanoid precursor units being connected at carbons other than C-8 to C-8′, these compounds are sometimes classified as 8,3′–neolignans. In addition to the isomeric possibilities caused by the stereogenic center in the 7, 8–dihydrofuran ring, there are also many possible modifications of the propyl chain of this class of molecules.

There were 26 benzofuran-type lignans isolated from plants and tested for antiviral activity (392–417) in the time period covered by this review (see Table 1 for source plants, antiviral activities, and references). The benzofuran lignans tested between 1998 and 2020 displayed the least antiviral activity of all of the classes of lignans. The most active benzofuran lignans were 403 and 406, however, there were none with EC50 values ≤ 5 μM. There were no antiviral studies on synthetic lignans of this class.

figure ac

Vladinol F (403), a lignan isolated from the leaves and stems of Schisandra micrantha (Yunnan, China), displayed anti-HIV-1 activity with an EC50 value of 9.75 μM and a TI value of 27.45 (Li et al. 2005a). Balaphonin (406) was obtained from the leaves and stems of S. lancifolia (Yunnan, China). It showed anti-HIV-1 effects with an EC50 value of 8.43 μM and a TI value of 4.3, respectively (Xiao et al. 2010b).

figure ad

Neolignans

figure ae

Neolignans are phenylpropanoid dimers connected at positions other than C-8/C-8′. Here, we are focusing on neolignans biosynthesized by connection of the C-3/C-3′ carbons in the phenylpropanoid precursors, or via an ether linkage.

Compounds 418–436 represent the 19 neolignans isolated from plants and tested for antiviral activity between 1998 and 2020 (see Table 1 for source plants, antiviral activities, and references). There were three plant-derived neolignans that exhibited EC50 values ≤ 5 μM (424, 429, 436). Among this type of compounds, 424 may be considered as a lead molecule against HBV infection with a high TI value. There were 5 synthetic neolignans (437–441) made and assayed for antiviral activity.

Seven neolignans, (7′S,8′S)–trans–streblusol A (418), (7′R,8′S)–erythro–streblusol B (419), (7′S,8′S)–threo–streblusol B (420), 8′R-streblusol C (421), (8R,8′R)-streblusol D (422), threo-strebluslignanol (423) and magnolol (424) were isolated from the stem bark of Streblus asper (Moraceae, Guangxi, China). Magnolol (424) showed anti-HBV activities against HBsAg antigen with an EC50 value of 2.03 μM and a TI value of 31.37, and HBeAg antigen with an EC50 value of 3.76 μM and a TI value of 316.94 (Li et al. 2012a). (7R,8S,7′R,8′S)–erythro–Strebluslignanol H (428), -and honokiol (429) were isolated from the roots of the same plant. Among them, 429 exhibited anti-HBV activities with EC50 values of 3.14 μM (TI = 21.5) on HBsAg and 4.74 μM (TI = 14.2) against HBeAg (Chen et al. 2012). Compound 429 also displayed an antiviral effect against HCVcc infection at non-toxic concentrations. It inhibited the cell entry of lentiviral particles pseudo-typed with glycoproteins from HCV genotypes 1a, 1b, and 2a, but not the VSV. The expression levels of the components of replication complex, NS3, NS5A and NS5B, were down-regulated by 429 in a dose-dependent manner in the concentration range of 10–30 μM. The compound inhibited HCV replication dose dependently in both genotypes 1b and 2a sub-genomic replicons in the concentration of 10 and 20 μM. Therefore, it was determined that 429 inhibited HCV infection by targeting cell entry and replication with an EC50 value of 1.2 μM, an EC90 value of 6.5 μM, and a TI (LD50/EC90) value of 5.4 (Lan et al. 2012). Furthermore, during the evaluation for activity against anti-SARS-CoV using a cell-based assay measuring SARS-CoV-induced cytopathogenic effects on Vero E6 cells, 424 and 429 showed inhibitory activity at the concentrations between 10 and 20 μM by cell-based CPE assay, and they displayed appreciable levels of anti-SARS virus bioactivity with EC50 values ranging from 3.8 to 7.5 μM and the CC50 values of > 65 μM (Wen et al. 2007).

figure af

In a separate study, 12 neolignans including 423, 424, magnolignan A (430), magnolignan A-2-O-β-D-glucopyranoside (431), isostrebluslignanaldehyde (432), isomagnolol (433), obovatol (434), strebluslignanol F (435) and (7′R,8′S,7″R,8″S)-erythro-strebluslignanol G (436) were isolated from the roots of S. asper (Guangxi, China) and evaluated for their anti-HBV activities using the HBV transfected HepG2.2.15 cells. The neolignan 424 and the dimeric neolignan 436 displayed activities against anti-HBV with EC50 values of 2.03 (TI = 31.37) and 1.58 μM (TI = 74.90) for HBsAg, and with EC50 values of 3.76 (TI = 16.94) and 3.24 μM (TI = 36.52) for HBeAg. They also showed HBV DNA replication with EC50 values of 8.67 (TI = 7.34) and 9.02 μM (TI = 13.12), respectively (Li et al. 2013).

Five 1,4–benzodioxane neolignans eusiderin A (437), eusiderin B (438), eusiderin G (39), eusiderin M (440) and nitidanin (441) were synthesized and screened for their anti-HCV activity. They displayed inhibitory effects with the EC50 values of 30, 20, 25, 50 and 200 μM and the TI values of 1.21, > 6.25, 1.91, 2.57 and 2.32, respectively (Pilkington et al. 2018).

figure ag

Dibenzocyclooctadiene lignans and homolignans

figure ah

Dibenzocyclooctadiene lignans are defined by having a C-2/C-2′ linkage as well as the usual C-8/C-8′ juncture of the phenylpropanoid precursor units. This endows them with a cyclooctadiene ring. Unlike dibenzocyclooctadiene lignans, which have both aromatic rings intact, homolignans lack one of the 6-carbon aromatic ring moieties. In some cases, homolignans possess a cyclohexadienone moiety, and in some instances, the cyclohexadienone moiety has been cleaved.

Between 1998 and 2020, 157 dibenzyocyclooctadiene lignans and homolignans (442–598) were isolated from plants and tested for antiviral activity, by far the most of any class of lignan over this time period (see Table 1 for source plants, antiviral activities, and references). This class of lignan had 20 compounds with antiviral activity (≤ 5 μM), but the most interesting, due to their potent activities (EC50 ≤ 1 μM), are 480 and 591. There were no studies on synthetic dibenzyocyclooctadiene lignans or homolignans.

figure ai
figure aj

The lignans interiotherin B (443), angeloylgomisin R (444), schisantherin B (476), ( +)-gomisin K3 (477), rubrisandrins A and B (478–479), ( ±)-gomisin M1 (480), ( +)-gomisin M2 (481), deoxyschisandrin (482), schisandrin (483), tigloylgomisin P (484), gomisin O (485), angeloylgomisin P (486), epigomisin O (487), methylgomisin R (488), ( +)-14-tigloylgomisin K3 (489), 12-demethylwuweilignan I (490), schisandrene A (491), gomisin R (492), (R)-( +)-gomisin M1 (493), ( +)-angeloylgomisin K3 (494), dimethylgomisin J (495), rubrilignans A-B (496–497), schisantherin D (498), and gomisin J (499) were obtained from the extract of Schisandra rubriflora and their anti-HIV effects were evaluated (Chen et al. 2006; Li et al. 2008; Mu et al. 2011). Among them, rubrisandrin A (478), gomisin J (499), ( ±)-gomisin M1 (480), ( +)-gomisin M2 (481) and ( +)-gomisin K3 (477) were active in the HIV growth inhibition assay with EC50 values 11.3, 3.9, < 0.65, 2.4 and 5.7 μM, and TI values of > 5.7, 6.0, > 68, 19.4 and 7.4, respectively (Chen et al. 2006). Compound 480 possessed anti-HIV activity against a wide variety of HIV-1 and HIV-2 viral strains such as NL 4–3 (X4), Bal (R5), (B) BK132 (X4), (AE) 92TH001 (R5) and CBL-23 with EC50 values in the range of 1–3 µM. Further investigation indicated that 480 was a non-nucleoside reverse transcriptase inhibitor (NNRTI). The studies in TZM-bl indicator cells showed 480 exerted inhibitory activity against both NL 4–3 and BaL, suggesting that it targets an early step in the HIV life cycle. Quantitative real-time PCR demonstrated that 480 blocked both early and late HIV-1 reverse transcription products (Han et al. 2015). Compounds 496 and 497 showed anti-HIV-1 activities with EC50 values of 4.77 and 3.84 µM, and TI of 35.5 and 18.6, respectively (Mu et al. 2011).

figure ak
figure al
figure am

Phytochemical investigation of Kadsura angustifolia (Schisandraceae, Yunnan, China) led to 19 dibenzocyclooctadiene lignans kadangustins A-G (510–516), schisantherins Q (517) and L (507), gomisin R (492), deangeloylschisantherin F (518), schisantherin F (519), binankadsurin A (520), kadsulignan K (521), epoxideschisandrin C (522), kadsurarin (373), kadsulignan N (466), schisantherin P (508) and kadsulignan L (509). Compound 520 showed anti-HIV activity with an EC50 value of 3.86 µM (Gao et al. 2008).

From the stems of Kadsura heteroclita (Schisandraceae, Yunnan, China), dibenzocyclooctadiene lignans were obtained, including kadsulignan K (521), heteroclitins I (523) and J (524), acetoxyl oxokadsurane (525), benzoyl oxokadsurane (526), interiorin B (527), interiorin (451), heteroclitin D (453) and kadsurin (454). Compounds 451 and 527 exhibited anti-HIV-1 activity with EC50 values of 3.3 and 2.9 µM, and therapeutic index values of 52.9 and 65.9, respectively (Pu et al. 2008b).

figure an

Twelve new dibenzocyclooctadiene lignans, marlignans A-L (558–573), were obtained from the leaves and stems of Schisandra wilsoniana (Yunnan, China). Compounds 562–564, 567–569 showed anti-HIV-1 activities with EC50 values of 3.6, 3.3, 4.1, 4.1, 4.7, and 3.5 μM and the TI values of 8.7, 15.6, 6.7, 9.3, 7.7, and 16.4, respectively (Yang et al. 2010c). Two new dibenzocyclooctadiene ligans, schinegllignans A and B (613, 614), were isolated from the fruits of Schisandra neglecta (Schisandraceae, Yunnan, China). Compounds 613 showed anti-HIV-1 activities in C8166 cells with a EC50 value of 4.6 and TI value of 18.5 (Duan et al. 2011).

figure ao
figure ap

From the stems of Schisandra neglecta (Schisandraceae, Sichuan, China), the new lignans neglignans A-B (590, 591) and E–G (592–594) and the known compounds rubschisantherin (583), gomisins D (585), T (595), F (596), angeloylgomisin Q (597) and schisphenin F (598) were obtained. Copmounds 583, 585, and 590–598 showed anti-HIV-1 activities with EC50 values of 4.7, 9.8, 2.2, 1.4, 5.9, 3.5, 8.2, 8.2, 8.3, 11.5 and 8.3 μM, and TI values of 18.2, 18.9, 40.3, 55.3, > 33.7, > 58.0, 18.1, 15.1, 7.5, 7.4 and 17.8, respectively (Gao et al. 2013).

Norlignans and other lignoids

Norlignans are structures formed by the conjunction of two phenylpropanoid units followed by loss of one carbon from the skeleton. This section covers these compounds, as well as those formed from two phenylpropanoid units, but have undergone skeletal rearrangements or cleavages, termed lignoids. This includes secolignans as well as structures that have seemingly had one of the propyl side-chains completely removed.

During the time covered by this review, 32 norlignans and lignoids isolated from plants were tested for antiviral activity (599–630) (see Table 1 for source plants, antiviral activities, and references). Of the plant-derived norlignans and lignoids, only compounds 605 and 612 displayed antiviral activity at concentrations at or below 1 μM. We found no evidence of synthetic norlignans or lignoids bioassayed for antiviral activity.

figure aq

Three 7,8-secolignans, marphenols A and B (605–606) together with 7,8-secoholostylone B (607), were isolated from the stems of Schisandra wilsoniana (Schisandraceae, Yunnan, China). Compounds 605–607 inhibited HIV-1IIIB-induced syncytia formation with EC50 values of 1.5, 4.5, 5.4 μM and TI values of 18.27, 4.33 and 9.19, respectively. In a further study of the anti-HIV-1 activity, 605 reduced p24 production in acute HIV-1IIIB-infected C8166 cells with an EC50 value of 9.0 μM, and inhibited primary isolate HIV-1TC-2 replication in PBMCs with an EC50 value of 1.4 μM. However, the compound did not inhibit p24 expression and had no effects on cell to cell fusion in chronically infected H9 cells (Zhang et al. 2010).

figure ar

(1S)–4–Hydroxy–3–[2–(4–hydroxyl–3–methoxy–phenyl)–1–hydroxymethyl–2–oxo–ethyl]–5–methoxy–benzaldehyde (612) was isolated from the seeds of Herpetospermum caudigerum (Cucurbitaceae, Sichuan, China) and displayed inhibitory activity against HBV on HBsAg and HBeAg secretions with EC50 values of 0.34 and 4.83 × 10–4 μM, respectively, and low cytotoxicity against HepG 2.2.15 cell line with a CC50 value of 2.96 × 105 μM (Yu et al. 2014).

figure as

Disscussion

Hundreds of lignans with anti-viral activities were reported from 66 different plant species, belonging to 43 genera, and 34 different families (Table 1). Among them, the genera Kadsura, Phyllanthus and Schisandra contained numerous active lignans with anti-HIV and anti-HBV activities.

Of the 630 lignans and lignoids covered in this review, 153 of them were arylnaphthalene lignans, 73 were aryltetralin lignans, 22 were dibenzylbutyrolactone lignans, 39 were dibenzylbutane lignans, 104 were tetrahydrofuranoid and tetrahydrofurofuranoid lignans, 26 were benzofuran lignans, 24 were neolignans, 157 were dibenzocyclooctadiene lignans and homolignans, and 32 were norlignans and other lignoids. Although aryltetralin and arylnaphthalene lignans have received the most attention in regards to synthesis, and structure–activity-relationship, due in large part to the clinical and commercial success of podophyllotoxin and the promising results of diphyllin (11) and helioxanthin (32), the other classes of lignans and lignoids are also deserving of increased scientific exploration as antiviral lead compounds (Table 2).

Table 2 Comparison of antiviral lignan and lignoid classes from 1998–2020
Full size table

There remain multitudes of lignans and lignoids in all of the categories that have not been tested for antiviral activity, an endeavor that could reveal additional potent potential drugs. Further standardization of antiviral assays could also be beneficial in doing direct comparisons and for SAR studies (a poignant example is compound 627, which has two EC50 values against HIV reported, one 44.68 μM, and one 104 μM).

Between 1963 and 2020, about 200 antiviral drugs were approved for treatment of viral infection. Most of them came from chemical synthesis or structural modifications of natural products (Clercq and Li 2016; Chaudhuri et al. 2018; FDA 2018, 2019, 2020). Although the isolated natural products normally exhibited moderate to weak antiviral activities, some did show excellent antiviral activities. For example, patentiflorin A (153), the 6-deoxyglucoside derivatives of diphyllin, which were isolated from Justicia plants, and shown to potently inhibit a broad spectrum of HIV-1 strains including some resistant strains with EC50 values in the range of 15–37 nM (AZT: 77–95 nM) and mosquito-borne flavivirus such as ZIKV, DENV1, TBEV, WNV, JEV and EBV with EC50 values ranged between 0.12–1.0 μM (Zhang et al. 2017a, 2017b; Martinez-Lopez et al. 2019). Helioxanthin (32) is an arylnaphthalene type lignan obtained from the roots of Heliopsis scabra Dunal (Asteraceae, Taiwan, China) and the aerial parts of Taiwania cryptomerioides Hayata (Taxodiaceae, Taiwan, China). It caught the attention of chemists because of its potent inhibition against HBV gene expression in vitro with an EC50 value of 1 μM and an ID50 value of 31 μM against CEM cell line (Yeo et al. 2005). In a study focusing on the molecular mode of action of 32 on HBV gene expression, this compound was found to suppress the surface antigen promoter (SP) II and the core promoter (CP) selectively, but it had no effect on SPI or the promoter for the X gene. In addition, the suppressive effects on both SPII and CP activity were liver-specific. In another study, compound 32 reduced the DNA-binding activity of the nuclear extract of HepA2 cells to the specific cis element of the HBV promoter for the core antigen, including peroxisome proliferator-activated receptors (PPARs), the PPAR binding site, and the transcription factors α-fetoprotein and specificity protein 1 (Sp1). Moreover, the ectopic expression of PPARγ or HNF4α partially reversed the suppression of HBV RNA by 32. Hence, compound 32 may represent a novel class of anti-HBV agents that can selectively modulate the transcriptional machinery of human liver cells to reduce HBV gene expression and replication (Tseng et al. 2008; Li et al. 2005b). More than 100 derivatives of helioxanthin were synthesised. Among them, the lactam 49 and the cyclic hydrazide derivative 59 exhibited significant inhibitory activity against wild mutant HBV with the EC50 values of 0.08 and 0.03 μM, respectively (Yeo et al. 2005). Compound 49 also inhibited HBV against the drug resistant mutants W10 and DM2 with the EC50 values of 0.004 and 0.0003 μM, respectively (Li et al. 2005b; Cheng et al. 2005a; Tseng et al. 2008). These studies revealed that natural lignans are an important source for the discovery of novel antiviral agents and should be further exploited as lead compounds. Since many lignans have demonstrated antiviral activities, extensive exploration of them through phytochemical studies, chemical synthesis, structure modification, structure–activity relationship analysis and mechanism of action studies could bring next generation of antiviral drugs.